Any loss sustained duringthe taxable year can be claimed as a tax deduction
Midlantic Urology’s Dr. Dean Laganosky is first US urologist to implant FDA-approved balloon spacer for prostate cancer
“This next-generation rectal spacing option is the first of its kind...and has the potential to provide an enhanced degree of protection from the genitourinary and rectal effects of prostate cancer radiation therapy,” said Dr. Laganosky.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
FDA grants cretostimogene grenadenorepvec Breakthrough and Fast Track Designations for NMIBC
The designations, which will expedite the development and regulatory review of cretostimogene grenadenorepvec in this setting, are supported by results from the phase 3 BOND-003 trial.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
FDA grants TAR-200 Breakthrough Therapy Designation for BCG-unresponsive NMIBC
The designation, which will expedite the development and regulatory review of TAR-200 in this setting, is based on findings from the phase 2b SUNRISE-1 trial.
Phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer launches
According to Clarity Pharmaceuticals, the final results are intended to support an application to the FDA for approval of 64Cu-SAR-bisPSMA for imaging in patients with prostate cancer.
2 Clarke Drive Cranbury, NJ 08512